United States v. Mejia

Court of Appeals for the First Circuit·Decided December 2, 2022·No. 21-1815P·Published

Opinion

United States Court of Appeals For the First Circuit

No. 21-1815 UNITED STATES OF AMERICA, Appellee,

v.

JULIO MEJIA, a/k/a Carlos, Defendant, Appellant.

APPEAL FROM THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF MAINE

[Hon. D. Brock Hornby, U.S. District Judge]

Before

Barron, Chief Judge,

Selya and Gelpí, Circuit Judges.

Thomas J. Gleason and Gleason Law Offices, P.C. on brief for appellant.

Kenneth A. Polite, Jr., Assistant Attorney General, Criminal Division, United States Department of Justice, Lisa H. Miller, Deputy Assistant Attorney General, Criminal Division, W. Connor Winn, Criminal Division, Appellate Section, Darcie N. McElwee, United States Attorney, Benjamin M. Block, Chief, Appellate Division, Johnathan G. Nathans, Assistant United States Attorney, on brief for appellee.

November 8, 2022

SELYA, Circuit Judge. In this case, the district court allowed the government to rescind a plea agreement previously entered into with defendant-appellant Julio Mejia and proceeded to sentence the defendant to a 162-month term of immurement. The defendant appeals, arguing that the court should not have allowed the rescission of the plea agreement and that, compounding this blunder, the court miscalculated drug quantity and incorrectly imposed a role-in-the-offense enhancement. Concluding, as we do, that the defendant is foraging in an empty cupboard, we affirm.

I

We briefly rehearse the relevant facts and travel of the case. "Where, as here, a sentencing appeal follows a guilty plea, we glean the relevant facts from the change-of-plea colloquy, the unchallenged portions of the presentence investigation report (PSI Report), and the record of the disposition hearing." United States v. Vargas, 560 F.3d 45, 47 (1st Cir. 2009).

In 2016, the authorities began investigating a sprawling drug-trafficking organization that was supplying significant amounts of cocaine and fentanyl to drug dealers throughout Maine, New Hampshire, and Massachusetts. The defendant was involved hip- deep in the activities of the organization: at least until the end of 2016, he received orders from customers, set drug prices, and arranged the itineraries for drug couriers.

In December of 2016, the defendant turned over his list of customers to an associate, Inyemar Manuel Suazo, and departed for the Dominican Republic. His departure left Suazo in charge. But after the defendant returned to the United States on May 7, 2017, he both resumed contact with Suazo and resumed involvement in the original drug-trafficking organization. By September, though, the two men had gone their separate ways, and the defendant began running his own drug-trafficking enterprise.

The defendant's new enterprise involved some persons who had been participants in the original drug-trafficking organization. This roster of past participants included a courier, Rafael Espinal-Calderon. The defendant continued distributing cocaine and fentanyl through this new network until his arrest in 2018.

In due course, a federal grand jury sitting in the District of Maine charged the defendant with conspiracy to distribute and to possess with intent to distribute 400 grams or more of a mixture or substance containing fentanyl. See 21 U.S.C. §§ 841(a)(1), 846. The defendant initially maintained his innocence, but he later changed his plea, pursuant to a written plea agreement. The district court accepted the defendant's guilty plea and ordered the preparation of a PSI Report.

When received, the PSI Report recommended a criminal history category of I and a total offense level (TOL) of forty-

three. The TOL included a drug quantity attribution, see USSG §2D1.1, a role-in-the-offense enhancement based on the defendant's asserted leadership of "criminal activity that involved five or more participants," id. §3B1.1(a), and a reduction for acceptance of responsibility, see id. §3E1.1. The guideline recommendations limned in the PSI Report yielded a guideline sentencing range of life imprisonment.

In March of 2019, the defendant entered into a cooperation agreement with the government, which both merged into and supplemented his plea agreement. (For ease in exposition, we henceforth refer to the plea agreement and the cooperation agreement, collectively, as the "supplemented plea agreement.") Pursuant to the supplemented plea agreement, the defendant pledged to assist the government's ongoing investigation into drug- trafficking activities in various ways (including testifying when requested). For its part, the government pledged not to use any of the information provided by the defendant against him, to make his cooperation known upon his request, and to recommend a three- level reduction for acceptance of responsibility under USSG §3E1.1.

The defendant began cooperating with the government and continued his assistance until November 27, 2020. At some time prior to that date, Suazo apparently approached the defendant, showed him a copy of the cooperation agreement, and threatened to

post it online if the defendant testified. Fearing for his and his family's safety, the defendant subsequently refused to testify against Suazo.

The government responded to this development by announcing that it would treat the supplemented plea agreement as a nullity. The defendant tried to parry this thrust: he moved either to scrap the indictment or to enforce the supplemented plea agreement because the government had breached the latter by withdrawing it "in bad faith." After determining that the defendant's failure to testify against Suazo constituted a material breach of the terms of the supplemented plea agreement, the court denied the motion.

On September 27, 2021, the district court convened the disposition hearing in the defendant's case. The government reminded the court that the supplemented plea agreement had been abrogated by the defendant's refusal to testify and, therefore, should be deemed withdrawn. The defendant did not contemporaneously object to the rescission of the supplemented plea agreement, but his counsel urged the court to acknowledge the defendant's cooperation when weighing the sentencing factors made pertinent under 18 U.S.C. § 3553(a). Consequently, the supplemented plea agreement was rejected by the court.

The disposition hearing devolved principally into an exchange of views about the appropriateness vel non of the drug-

quantity and role-in-the-offense recommendations contained in the PSI Report. Amidst the sparring, the government suggested a 240- month term of immurement, and the defendant suggested half that time.

Regarding drug quantity, the district court concluded that the PSI Report's figure (114,362.6618 kilograms of converted drug weight)1 was "supportable based upon the testimony of runners like Espinal-Calderon and others." And with respect to the four- level role-in-the-offense enhancement, the court found that the evidence "without a doubt [] satisfie[d] the five participant level" and made "absolutely clear that this defendant was the leader."

After considering the section 3553(a) factors, the court concluded that the defendant "deserve[d] to be penalized far more heavily than the other members of the conspiracy." Even so, the court noted that the guideline sentencing range was "extraordinarily punitive and high" and that the defendant's cooperation, though not in full compliance with the supplemented plea agreement, ought to "have a major impact in terms of the sentence" to be imposed. The court settled upon a 162-month term

1 Where, as here, more than one type of drug is involved in an offense, the quantity of each drug is multiplied by a conversion factor to yield converted drug weight, so that quantities of different drugs may be combined into a single number for purposes of establishing the defendant's base offense level. See USSG §2D1.1(c), n.(K).

of immurement — a downwardly variant sentence that amounted to one half of the bottom of the adjusted guideline sentencing range.

This timely appeal followed.

II

Free access — add to your briefcase to read the full text and ask questions with AI

United States v. Mejia, (1st Cir. 2022).

United States v. Mejia (United States v. Mejia) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

United States v. Cintrón-Echautegui
604 F.3d 1 (First Circuit, 2010)
United States v. Clark
55 F.3d 9 (First Circuit, 1995)
United States v. Graciani
61 F.3d 70 (First Circuit, 1995)
United States v. Alegria
192 F.3d 179 (First Circuit, 1999)
United States v. Piper
298 F.3d 47 (First Circuit, 2002)
United States v. Santos
357 F.3d 136 (First Circuit, 2004)
Teragram Corporation v. MarketWatch.com,Inc.
444 F.3d 1 (First Circuit, 2006)
United States v. Vargas
560 F.3d 45 (First Circuit, 2009)
United States v. Juventino Carrillo
709 F.2d 35 (Ninth Circuit, 1983)
United States v. John F. Dunn, Jr.
758 F.2d 30 (First Circuit, 1985)
United States v. Aloyisius Juodakis
834 F.2d 1099 (First Circuit, 1987)
United States v. Ilario M.A. Zannino
895 F.2d 1 (First Circuit, 1990)
United States v. Bernier
660 F.3d 543 (First Circuit, 2011)
United States v. John Doe
233 F.3d 642 (First Circuit, 2000)
United States v. Rafael Ventura
353 F.3d 84 (First Circuit, 2003)
United States v. Flores-Machicote
706 F.3d 16 (First Circuit, 2013)
United States v. Almonte-Nunez
771 F.3d 84 (First Circuit, 2014)
United States v. Lilly
810 F.3d 1205 (Tenth Circuit, 2016)